The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients
Abstract
The proteasome inhibitor bortezomib may increase osteoblast-related markers in multiple myeloma (MM) patients; however, its potential osteoblastic stimulatory effect is not known. In this study, we show that bortezomib significantly induced a stimulatory effect on osteoblast markers in human mesenchymal cells without affecting the number of osteoblast progenitors in bone marrow cultures or the viability of mature osteoblasts. Consistently we found that bortezomib significantly increased the transcription factor Runx2/Cbfa1 activity in human osteoblast progenitors and osteoblasts without affecting nuclear and cytoplasmatic active β-catenin levels. Consequently a stimulatory effect of bortezomib on bone nodule formation was also demonstrated in osteoblast progenitors. These in vitro observations were confirmed in vivo by the finding of a significant increase in the number of osteoblastic cells × mm2 of bone tissue and in the number of Runx2/Cbfa1-positive osteoblastic cells that was observed in MM patients who responded to bortezomib. Our in vitro and in vivo observations support the hypothesis that a direct stimulatory effect on bone formation process could occur during bortezomib treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Hideshima, T., Richardson, P. G. G., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., & Anderson, K. C. (2001) · PubMed · Cited by 1,508
Tian, E., Zhan, F., Walker, R., Rasmussen, E., Ma, Y., Barlogie, B., & Shaughnessy, J. D. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030847 · Cited by 1,503
Regulation of osteoblast differentiation by transcription factors
Komori, T. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20958 · Cited by 1,023
Wnt signaling in osteoblasts and bone diseases
Westendorf, J. J., Kahler, R. A., & Schroeder, T. M. (2004) · Gene · doi:10.1016/j.gene.2004.06.044 · Cited by 808
BMP-2 Controls Alkaline Phosphatase Expression and Osteoblast Mineralization by a Wnt Autocrine Loop
Rawadi, G., Vayssière, B., Dunn, F., Baron, R., & Roman-Roman, S. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.10.1842 · Cited by 764
Development of a sensitive multi-well colorimetric assay for active NFkappaB
Renard, P. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.4.e21 · Cited by 359
Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2
Oshima, T., Abe, M., Asano, J., Hara, T., Kitazoe, K., Sekimoto, E., Tanaka, Y., Shibata, H., Hashimoto, T., Ozaki, S., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4940 · Cited by 345
Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro
Garrett, I. R., Chen, D., Gutierrez, G., Zhao, M., Escobedo, A., Rossini, G., Harris, S. E., Gallwitz, W., Kim, K. B., Hu, S., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16198 · Cited by 328
Giuliani, N., Colla, S., Morandi, F., Lazzaretti, M., Sala, R., Bonomini, S., Grano, M., Colucci, S., Svaldi, M., & Rizzoli, V. (2005) · Blood · doi:10.1182/blood-2004-12-4986 · Cited by 325
Self-citationMultiple myeloma bone disease: pathophysiology of osteoblast inhibition
Giuliani, N., Rizzoli, V., & Roodman, G. D. (2006) · Blood · doi:10.1182/blood-2006-05-026112 · Cited by 302
Self-citationZhao, M., Qiao, M., Oyajobi, B. O., Mundy, G. R., & Chen, D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304132200 · Cited by 279
Giuliani, N., Pedrazzoni, M., Negri, G., Passeri, G., Impicciatore, M., & Girasole, G. (1998) · Bone · doi:10.1016/s8756-3282(98)00033-7 · Cited by 269
Self-citationBataille, R., Chappard, D., Marcelli, C., Dessauw, P., Sany, J., Baldet, P., & Alexandre, C. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.12.1909 · Cited by 241
Shipman, C. M., & Croucher, P. I. (2003) · PubMed · Cited by 241
Shui, C., Spelsberg, T. C., Riggs, B. L., & Khosla, S. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.2.213 · Cited by 232
Terpos, E., Heath, D. J., Rahemtulla, A., Zervas, K., Chantry, A., Anagnostopoulos, A., Pouli, A., Katodritou, E., Verrou, E., Vervessou, E., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06356.x · Cited by 221
IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma
Ehrlich, L. A., Chung, H. Y., Ghobrial, I., Choi, S. J., Morandi, F., Colla, S., Rizzoli, V., Roodman, G. D., & Giuliani, N. (2005) · Blood · doi:10.1182/blood-2005-03-1080 · Cited by 208
Self-citationResponse to bortezomib is associated to osteoblastic activation in patients with multiple myeloma
Zangari, M., Esseltine, D., Lee, C., Barlogie, B., Elice, F., Burns, M. J., Kang, S., Yaccoby, S., Najarian, K., Richardson, P., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05733.x · Cited by 199
Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment
Heider, U., Kaiser, M., Müller, C., Jakob, C., Zavrski, I., Schulz, C., Fleissner, C., Hecht, M., & Sezer, O. (2006) · European Journal of Haematology · doi:10.1111/j.1600-0609.2006.00692.x · Cited by 161
Yaccoby, S., Wezeman, M. J., Zangari, M., Walker, R. C., Cottler‐Fox, M., Gaddy, D., Ling, W., Saha, R., Barlogie, B., Tricot, G. J. K., et al. (2006) · PubMed · Cited by 159
Barillé‐Nion, S., Collette, M., Bataille, R., & Amiot, M. (1995) · Blood · doi:10.1182/blood.v86.8.3151.3151 · Cited by 138
Osteoblast stimulation in multiple myeloma lacking lytic bone lesions
Bataille, R., Chappard, D., Marcelli, C., Rossi, J., Dessauw, P., Baldet, P., Sany, J., & Alexandre, C. (1990) · British Journal of Haematology · doi:10.1111/j.1365-2141.1990.tb07904.x · Cited by 60
Shimazaki, C., Uchida, R., Nakano, S., Namura, K., Fuchida, S.-I., Okano, A., Okamoto, M., & Inaba, T. (2005) · Leukemia · doi:10.1038/sj.leu.2403758 · Cited by 54
Response to Bortezomib and Activation of Osteoblasts in Multiple Myeloma
Zangari, M., Yaccoby, S., Cavallo, F., Esseltine, D. L., & Tricot, G. J. K. (2006) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2006.n.047 · Cited by 50
The role of markers of bone remodeling in multiple myeloma
Terpos, E., Politou, M., & Rahemtulla, A. (2004) · Blood Reviews · doi:10.1016/j.blre.2004.06.001 · Cited by 48
Biochemical markers of bone metabolism in multiple myeloma
Terpos, E. (2006) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(06)80004-6 · Cited by 41
Proteasome inhibition in multiple myeloma
Kropff, M. H., Bisping, G., Wenning, D., Berdel, W. E., & Kienast, J. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.02.015 · Cited by 25
Cited by
Raab, M. S., Podar, K., Breitkreutz, I., Richardson, P. G., & Anderson, K. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60221-x · Cited by 697
Bartel, T. B., Haessler, J., Brown, T. L. Y., Shaughnessy, J. D., van Rhee, F., Anaissie, E., Alpe, T., Angtuaco, E., Walker, R., Epstein, J., et al. (2009) · Blood · doi:10.1182/blood-2009-03-213280 · Cited by 518
Bone metastasis: the importance of the neighbourhood
Croucher, P. I., McDonald, M. M., & Martin, T. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.44 · Cited by 479
Pathogenesis of myeloma bone disease
Roodman, G. D. (2009) · Leukemia · doi:10.1038/leu.2008.336 · Cited by 398
Bone marrow microenvironment and the identification of new targets for myeloma therapy
Podar, K., Chauhan, D., & Anderson, K. C. (2009) · Leukemia · doi:10.1038/leu.2008.259 · Cited by 337
Metadata
- Authors
- Giuliani, N., Morandi, F., Tagliaferri, S., Lazzaretti, M., Bonomini, S., Crugnola, M., Mancini, C., Martella, E., Ferrari, L., Tabilio, A., & Rizzoli, V.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2007-07-01
- Volume
- 110
- Issue
- 1
- Pages
- 334-338
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1992422220
- Cited by
- 267
- References
- 28
- FWCI
- 17.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.